Andrew Tomaras is the Chief Scientific Officer at Forge Therapeutics, a small biotechnology company that uses a unique approach to discover and develop novel-class anti-infective agents to combat the continued emergence and spread of antimicrobial resistance. Prior to joining Forge, Andrew was the Chief Scientific Officer at BacterioScan, where he led all research and development activities for the advancement of an in vitro diagnostic platform that detects and characterizes bacterial infections more efficiently than traditional methods. He started his industrial career by joining the Antibacterials Research Unit at Pfizer, where he held the positions of Principal Scientist and Senior Principal Scientist. While at Pfizer, Andrew's team focused on characterizing the risk of antimicrobial resistance generation amongst target pathogens for novel drug candidates portfolio-wide, and also identified new high-throughput screening modalities through which new antibiotic targets/pathways could be elucidated. Dr. Tomaras holds both A.B. and Ph.D. degrees in microbiology from Miami University and conducted his post-doctoral research in microbiology at the University of Colorado Health Sciences Center.